A B Supplementary Figure 1. (A) Western blots were performed on the three cell lines to analyze the levels of p-ERK, which is a key protein involved in.

Slides:

Advertisements

Similar presentations

Advertisements

Supplementary Figure S1

Supplementary Figure 1 Supplementary Figure 1. TWEAK is internalized and degraded following binding to Fn14-positive cells. A, Serum-starved human U118.

Supplementary Figures: Fig. 1, 2, and 3 show H1299 cells overexpressing Set7/9wt or H297A catalytic mutant and U2-OS, U2-OS Set7/9KD, and U2-OS Set7/9.

P-ERK β-tubulin VSShh + cyclopamine Supplementary Figure ESM 1a ERK MAP Kinase activity is not affected by Shh pathway activity. Western blot analysis.

Isosteviol derivatives induced apoptosis in Human lung cancer via targeting MEK/MAPK pathway: An in vitro and in vivo study Ahmed M Malki 1,,PhD Stephen.

Table S1. Hypoxia increases signaling through JNK in colon cancer cell lines in a cell-specific manner Shown are the ratios of c-Jun phosphorylation during.

Determining the Effect of Triclosan on the Growth of Cancer Cells Lydia Alf and Winnifred Bryant Ph. D. Department of Biology University of Wisconsin,

Fig. S1 1 Oxygen consumption rate (pmol/sec/10⁶cells) shLKB1#1 control * untreated 25 μM erlotinib H358 Vector LKB1 Oxygen consumption rate (pmol/sec/10⁶cells)

Cell lineStatus FGFR1 DMS-114Gene amplification NCI-H520Gene amplification NCI-H1581Gene amplification FGFR2 NCI-H716Gene amplification KATO-IIIGene amplification.

Table S1. HTS positive hits.. Figure S1. Isogenic bortezomib (Btz) resistant mouse and human cell models. The indicated human (MM.1S and U266) and mouse.

SIRTs inhibitor: Sirtinol Supplementary Figure S3A Supplementary Figure S3 Sirtinol but not EX527 or PDF-170 significantly enhances ithe cytotoxic and.

Supplementary Figure S1 Inhibition of AKT and S6 phosphorylation. After 4 h treatment with 1 µM of GDC-0941, EVSA-T parental, resistant Clone1, Clone2,

Supplementary Table S1. List of chemical inhibitors utilized in the current study. Supplementary Information.

Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Differential Responses of Human Papillary Thyroid.

Copyright © 2007 American Medical Association. All rights reserved.

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

Integrated genomic and proteomic analysis identifies PTEN loss and AKT/MTOR as drivers of resistance to MEK inhibitors in NSCLC cells Dianren Xia1, Lauren.

B A P-AXL P-AXL AXL AXL P-MET P-MET MET MET P-Akt-473 P-Akt-473 AKT

Figure 3. Elevation of p53 and its acetylation after treatment with FK866 and nicotinamide adenine dinucleotide (NAD+). Cells were treated for 72 hours.

Supplementary Figure 1 Lapatinib nM mM pEGFR MDA-MB231 EGFR pEGFR

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

WEE1 inhibition forces S-phase–arrested cancer cells into mitosis.

Yunguang Sun, PhD, Luigi Moretti, MD, Nicholas J

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

Rafal Dziadziuszko, MD, PhD, Anh T

Marieke A. de Graaff, Shruti Malu, Irma Guardiola, Alwine B

Synergistic action of dual IGF1/R and MEK inhibition sensitizes childhood acute lymphoblastic leukemia (ALL) cells to cytotoxic agents and involves downregulation.

Molecular Predictors of Sensitivity to the MET Inhibitor PHA in Lung Carcinoma Cells Daisuke Matsubara, MD, PhD, Shumpei Ishikawa, MD, PhD, Sachiko.

A B C Supplementary Figure S1. Trabectedin decreases viability of primary MPM cell cultures. A and B, dose-dependent impact of trabectedin on epithelioid.

A High Content Clonogenic Survival Drug Screen Identifies MEK Inhibitors as Potent Radiation Sensitizers for KRAS Mutant Non–Small-Cell Lung Cancer Steven.

Volume 191, Issue 1, Pages (January 2014)

Supplemental Information

The Zinc Ionophore PCI-5002 Radiosensitizes Non-small Cell Lung Cancer Cells by Enhancing Autophagic Cell Death Kwang Woon Kim, PhD, Christina K. Speirs,

A FOXO3a-BIM cascade mediates sensitivity to PARP and MEK inhibition

Curcumin, a nutritional supplement with antineoplastic activity, enhances leiomyoma cell apoptosis and decreases fibronectin expression Minnie Malik,

Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer Hiroyuki.

Fig. 2. Mutant KRAS mediates resistance to PARPi and sensitivity to PARPi and MEKi Mutant KRAS mediates resistance to PARPi and sensitivity to PARPi and.

Volume 120, Issue 6, Pages (March 2005)

Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung.

Volume 18, Issue 1, Pages (July 2010)

Drug network derived from the core EGFR interactome and combination strategy to overcome the resistant cells. Drug network derived from the core EGFR interactome.

Kavitha Gowrishankar, Stephanie Snoyman, Gulietta M. Pupo, Therese M

AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer Luigi Moretti, MD, Bo Li, MD, Kwang Woon Kim, PhD, Heidi Chen,

The Human Immunodeficiency Virus Protease Inhibitor Ritonavir Inhibits Lung Cancer Cells, in Part, by Inhibition of Survivin Anjaiah Srirangam, PhD,

PDGF regulates gap junction communication and connexin43 phosphorylation by PI 3- kinase in mesangial cells Jian Yao, Tetsuo Morioka, Takashi Oite Kidney.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

TBP 200 LC2/ad MGH134 MGH134 CCDC6-RET MGH134 EV CCDC6-RET PC9

Inhibition of CDK6 kinase activity sensitizes EOC cells to platinum in vitro Inhibition of CDK6 kinase activity sensitizes EOC cells to platinum in vitro.

Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive to MEK inhibition. Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive.

Volume 18, Issue 11, Pages (November 2011)

The RAF Inhibitor Paradox Revisited

Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer Edward.

Abemaciclib (µM) LY (µM)

Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines Wei Zhang, PhD, Michael.

Chi-Hyun Park, Youngji Moon, Chung Min Shin, Jin Ho Chung

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer Philip C. Mack,

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

Leto et al., Supplementary Figure S3

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib Kenichi.

Elevated Expression of BIRC6 Protein in Non–Small-Cell Lung Cancers is Associated with Cancer Recurrence and Chemoresistance Xin Dong, MD, Dong Lin,

Volume 18, Issue 11, Pages (November 2011)

Radiosensitization by combined Wee1 and PARP inhibition.

A, one-step viral growth curves: RT treatment increased the virus yield in MV-CEA–treated U87 cells by up to 2 log as compared with MV-CEA infection only.

KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition. KRAS mutation leads to resistance to combined RAF/EGFR and RAF/MEK inhibition.

MEK1F53L mutation drives clinical acquired resistance to combined RAF/MEK inhibition. MEK1F53L mutation drives clinical acquired resistance to combined.

Differential effects of the RAF inhibitor PLX4032 in BRAF-mutant melanoma, thyroid, and colorectal cancer cell lines. Differential effects of the RAF inhibitor.

Combining IGF1R inhibitors with MEK or RAF inhibitors enhances the differential impact upon mutant KRAS cells. Combining IGF1R inhibitors with MEK or RAF.

Volume 21, Issue 4, Pages (February 2006)

Presentation transcript:

A B Supplementary Figure 1. (A) Western blots were performed on the three cell lines to analyze the levels of p-ERK, which is a key protein involved in cellular proliferation and growth. The treatment of the three cell lines with GSK led to a reduction in p-ERK with both increasing concentrations (0-100nM) and increasing time after the administration of 10nM (0-24hrs); Dose enhancing ratios corresponding to figure 5A.

A Supplementary Figure 2. (A) MTS assays on additional cell lines (e.g. H23, SK-LU-1, and Calu-1) were performed with increasing concentrations of both MEKi and CDKi; (B)Kras mutant NSCLC cell lines treated with the GSK , PD , or the combination for 72h. Green squares represent significant effect, yellow squares indicate over less than 50% of the effect range, and red squares show lack of significant effect. Mutational status of cell lines obtained from the Sanger Cancer Cell Line Project ( and The TP53 Mutation Database ( Abbreviations: NSCLC, non–small cell lung cancer not otherwise specified; wt, wild- type; Del, deletion. B

Supplementary Figure 3.. Cells were treated with various concentrations of GSK in combination with PD for 72 hours, and cell viability was measured by MTS assay (left). The combination index value was determined from the fraction-affected value of each combination according to the Chou-Talalay method by using CompuSyn software (ComboSyn, Inc.), and a combination index value below 1 represents synergism. H358 demonstrated no synergism when MEKi and CDKi were coadministered (right).

Supplementary Figure 4. Isobologram for the combination of GSK with PD in A549 and H460 cell lines. X-axis means concentration of GSK (nM), y-axis means concentration of PD (nM).

A549 H p-RB 807 RB p-ERK ERK PARP H358 GSK112 RT 6Gy β-Actin c-PARP Supplemantry FIgure 5. MEK inhibitor enhances radiosensitivity of KRAS mutant NSCLC cell lines. Western blots were performed demonstrating that MEK inhibitor enhanced radiosensitizing effect via activated RB in the sensitive cell line H358, with little effect on the more resistant cell lines (A549 and H460).